Leerink Partners cuts Travere Therapeutics target price to $67 from $78
TVTX•Leerink Partners cut its target price for Travere Therapeutics to $67 from $78.
Related News
Lumentum Holdings Inc.: B. Riley cuts to neutral from buy, target to $770 from $1,142
LITE•
Bolt Biotherapeutics to participate in Stifel and Jefferies healthcare conferences
BOLT•
Sysco names Brandon Sewell chief financial officer
SYY•
Taco Bell sales fall more than expected on cyclosporiasis outbreak hit
YUM•
RTX's Raytheon wins DARPA contract to develop light-based signal processing technology
RTX•